Mcia Inc Abb Vie Inc. Transaction History

Mcia Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 12, 2021	SELL	$80.49 - $108.67 $351,419 - $474,453	-4,366 Closed	0 $0
Q3 2020 Oct 13, 2020	SELL	$85.91 - $100.83 $2.83 Million - $3.32 Million	-32,898 Reduced 88.28%	4,366 $386,000
Q2 2020 Jul 08, 2020	BUY	$73.37 - $98.18 $2.44 Million - $3.26 Million	33,208 Added 818.74%	37,264 $3.7 Million
Q1 2020 Apr 13, 2020	SELL	$64.5 - $97.79 $4,257 - $6,454	-66 Reduced 1.6%	4,056 $323,000
Q4 2019 Jan 09, 2020	SELL	$72.13 - $90.25 $138,345 - $173,099	-1,918 Reduced 31.75%	4,122 $369,000
Q3 2019 Oct 25, 2019	BUY	$62.98 - $75.72 $15,367 - $18,475	244 Added 4.21%	6,040 $457,000
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $153,015 - $195,589	2,329 Added 67.18%	5,796 $377,000
Q1 2019 May 16, 2019	BUY	$77.14 - $90.79 $267,444 - $314,768	3,467 New	3,467 $279,000
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $60,542 - $66,389	-676 Closed	0 $0
Q2 2017 Aug 16, 2017	BUY	N/A	676	676 $49,000

3,852

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Mcia Inc, based on Form 13F filings with the SEC.

Stay updated on Mcia Inc with notifications on news.